e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Other thoracic tumours, particular circumstances and rare cases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The proteasome subunits PSMA5 and PSMB4 are potent markers to discriminate between typical and atypical carcinoid tumors of the lung
F. Mairinger, R. Walter, T. Hager, C. Vollbrecht, D. Christoph, K. Worm, K. W. Schmid, J. Wohlschlaeger (Essen, Cologne, Germany)
Source:
Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Session:
Other thoracic tumours, particular circumstances and rare cases
Session type:
Thematic Poster Session
Number:
4523
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Mairinger, R. Walter, T. Hager, C. Vollbrecht, D. Christoph, K. Worm, K. W. Schmid, J. Wohlschlaeger (Essen, Cologne, Germany). The proteasome subunits PSMA5 and PSMB4 are potent markers to discriminate between typical and atypical carcinoid tumors of the lung. Eur Respir J 2013; 42: Suppl. 57, 4523
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Micro-RNA screening in neuroendocrine lung tumors: Differential expression of miR-29 family members
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Proapoptotic effects of PAI-1 protein on lung and prostate cancer cells
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Expression and clinical implications of the estrogen receptor β in lung adenocarcinoma
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Hyaluronidase, hyaluronan synthase, E-cadherin and TGF-beta profile in lung adenocarcinoma subtypes and squamous cell carcinoma of smokers/nonsmokers
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Mouse lung adenocarcinoma cell lines reveal Prl2c2 as a novel lung tumor promoter
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP)
Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy
Year: 2013
Aromatase inhibition alters the mechanical properties of non small-cell lung cancer cells affecting cell movement
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Expression of the ILK-PINCH-PARVIN (IPP) complex and its binding partner Rsu-1 in human non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
MUC1 associates with smoking, prognosis and histological subtypes in lung adenocarcinoma
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Correlation between clinical and pathological factors in resected lung carcinoid tumours
Source: International Congress 2016 – Special issues in thoracic surgery
Year: 2016
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Expression and clinical significance of S100 calcium binding protein A2 in lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Telomere-associated gene network in lung adenocarcinoma
Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept